Xilio Therapeutics, Inc. (XLO) News
Filter XLO News Items
XLO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XLO News Highlights
- For XLO, its 30 day story count is now at 2.
- Over the past 28 days, the trend for XLO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CRC, FC and MG are the most mentioned tickers in articles about XLO.
Latest XLO News From Around the Web
Below are the latest news stories about XILIO THERAPEUTICS INC that investors may wish to consider to help them evaluate XLO as an investment opportunity.
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataPhase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) Updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose (RP2D) continues to demonstrate minimal treatment-related adverse events, consistent with tumor-activated molecule design, and a 33% disease control rate across a range of late-line and IO refractory advanced solid tumors Previously reported confirmed partial response with XTX101 monotherapy |
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsDemonstrated initial clinical validation of tumor-selective activation technology for both XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and XTX202, a tumor-activated, beta-gamma IL-2 On track to activate trial sites for XTX101 dose escalation in combination with atezolizumab under clinical collaboration with Roche in the fourth quarter of 2023 Reported initial Phase 1/2 data for XTX202, including a 50% disease control rate at higher doses (≥2.8 mg/kg), and plans to evaluate XTX202 as mono |
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsInitial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors Treatment-related adverse events primarily Grade 1-2 at doses up to 4 mg/kg administered once every three weeks in outpatient setting, with no reported signs or symptoms of vascular leak syndrome Two patients continuing treatment for more than 1 year, demonstrating XTX202 was w |
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual MeetingWALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered |
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingWALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. The company plans to present preliminary anti-tumor activity, safety, pharmacokinetic and |
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development OfficerMartin Huber, M.D., to leave Xilio Therapeutics and remain an advisorWALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the promotion of Katarina Luptakova, M.D., to the role of chief medical officer and Scott Coleman, Ph.D., to the role of chief development officer, each effective as of September 5, 202 |
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceWALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 2:55 pm EST. A live webcast can be accessed under “Events & Presentat |
Q2 2023 Xilio Therapeutics Inc Earnings CallQ2 2023 Xilio Therapeutics Inc Earnings Call |
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial ResultsXilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®), in patients with microsatellite stable (MSS) colorectal cancer Xilio to host live virtual program spotlighting XTX101 on Thursday, August 17, 2023, at 12:30 p.m. ET Anticipate reporting preliminary Phase 1/2 data for XTX202, a tumor-activated IL-2, in early November 2023 Anticipate reporting preliminary Phase 1 safety data for X |
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating OfficerWALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the promotion of Chris Frankenfield to chief operating officer of Xilio. “Chris has played an integral strategic leadership role in supporting the growth and evolution of Xilio as a clinical-stage company,” said René Russo, Pharm.D., chief executive offic |